New drug approvals from FDA declined in 2013

by Matthew Perrone

(AP)—The Food and Drug Administration approved fewer first-of-a-kind drugs in 2013 compared with 2012, when new drug approvals reached a 15-year high.

The agency approved 27 innovative medicines last year, down from the 39 new medications cleared the year before.

Despite the decline, FDA officials say last year's tally is in line with the historical trend. On average, the FDA has approved 28 first-of-a-kind drugs over the last five years.

FDA approvals are watched closely by analysts as a barometer of industry innovation and the government's efficiency in reviewing new therapies.

Experts say the number of declined in 2013 mainly because there were fewer drugs submitted for review.

1 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

US House sends drug bill to Senate for final vote

Jun 20, 2012

(AP) — The House on Wednesday passed a major bill affecting the Food and Drug Administration that will increase inspections of drug manufacturing facilities overseas, while also funding review of new drugs at home.

US health watchdog rejects Sanofi's MS drug

Dec 30, 2013

French drug giant Sanofi announced Monday US health authorities had rejected its Lemtrada drug for some forms of multiple sclerosis, which is already approved in the European Union, Canada and Australia.

Recommended for you

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments